(PHVS) Pharvaris BV - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.023m USD | Total Return: 81.1% in 12m
Avg Turnover: 11.2M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Share dilution 19.8% YoY
Interest Coverage Ratio -1965.7 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
Confidence
Pharvaris N.V. (PHVS) is a clinical-stage biopharmaceutical company specialized in developing oral therapies for rare, bradykinin-mediated diseases. The firm’s primary focus is deucrictibant, a small molecule B2-receptor antagonist currently in Phase 3 trials for the treatment and prevention of hereditary angioedema (HAE) attacks.
The company operates within the orphan drug sector, a niche market characterized by high barriers to entry and regulatory incentives such as extended exclusivity periods. Unlike traditional injectable treatments for HAE, Pharvariss business model centers on developing small molecule formulations to provide patients with more convenient oral administration options.
To evaluate the long-term potential of these clinical assets, investors can explore the detailed risk assessments available on ValueRay.
Based in Switzerland, Pharvaris is advancing both immediate-release and extended-release versions of its lead candidate to address acute symptoms and long-term prophylaxis in patients with C1-inhibitor deficiencies.
- Phase 3 deucrictibant clinical trial results determine long-term commercial viability
- FDA regulatory approval timelines for oral HAE treatments impact valuation
- Market penetration against injectable competitors dictates future revenue growth potential
- Cash runway and R&D expenditure levels influence near-term financing requirements
- Expansion into prophylactic and on-demand treatment markets drives total addressable market size
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA -2.56 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.57 > 3% & CFO -148.2m > Net Income -169.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.3m) vs 12m ago 19.78% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -1.97k > 6 (EBITDA TTM -172.2m / Interest Expense TTM 87.8k) |
| A: 0.90 (Total Current Assets 258.0m - Total Current Liabilities 22.9m) / Total Assets 260.1m |
| B: -2.38 (Retained Earnings -620.2m / Total Assets 260.1m) |
| C: -0.68 (EBIT TTM -172.6m / Avg Total Assets 254.1m) |
| D: -23.83 (Book Value of Equity -559.5m / Total Liabilities 23.5m) |
| Altman-Z'' = -31.43 = D |
As of May 24, 2026, the stock is trading at USD 30.54 with a total of 308,788 shares traded.
Over the past week, the price has changed by -2.37%,
over one month by -1.20%,
over three months by +7.30% and
over the past year by +81.09%.
Pharvaris BV has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy PHVS.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 46.3 | 51.5% |
P/B = 7.3735
Revenue TTM = 0.0 EUR
EBIT TTM = -172.6m EUR
EBITDA TTM = -172.2m EUR
Long Term Debt = 533k EUR (estimated: total debt 740k - short term 207k)
Short Term Debt = 207k EUR (from shortTermDebt, last quarter)
Debt = 740k EUR (from shortLongTermDebtTotal, last quarter) (leases 739k already included)
Net Debt = -246.5m EUR (calculated: Debt 740k - CCE 247.2m)
Enterprise Value = 1.49b EUR (1.74b + Debt 740k - CCE 247.2m)
Interest Coverage Ratio = -1.97k (Ebit TTM -172.6m / Interest Expense TTM 87.8k)
EV/FCF = -10.07x (Enterprise Value 1.49b / FCF TTM -148.2m)
FCF Yield = -9.93% (FCF TTM -148.2m / Enterprise Value 1.49b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 5.74 (Enterprise Value 1.49b / Total Assets 260.1m)
Interest Expense / Debt = 11.87% (Interest Expense 87.8k / Debt 740k)
Taxrate = 21.0% (US default 21%)
NOPAT = -136.4m (EBIT -172.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.24 (Total Current Assets 258.0m / Total Current Liabilities 22.9m)
Debt / Equity = 0.00 (Debt 740k / totalStockholderEquity, last quarter 236.6m)
Debt / EBITDA = 1.43 (negative EBITDA) (Net Debt -246.5m / EBITDA -172.2m)
Debt / FCF = 1.66 (negative FCF - burning cash) (Net Debt -246.5m / FCF TTM -148.2m)
Total Stockholder Equity = 251.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -66.60% (Net Income -169.2m / Total Assets 260.1m)
RoE = -19.42% (Net Income TTM -169.2m / Total Stockholder Equity 871.3m)
RoCE = -19.80% (EBIT -172.6m / Capital Employed (Equity 871.3m + L.T.Debt 533k))
RoIC = -63.94% (negative operating profit) (NOPAT -136.4m / Invested Capital 213.3m)
WACC = 7.69% (E(1.74b)/V(1.74b) * Re(7.69%) + D(740k)/V(1.74b) * Rd(11.87%) * (1-Tc(0.21)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 10.38%
[DCF] Fair Price = unknown (Cash Flow -148.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.25 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.65 | Chg30d=+11.88% | Revisions=+45% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.67 | Chg30d=+11.52% | Revisions=+45% | Analysts=9
EPS current Year (2026-12-31): EPS=-2.58 | Chg30d=+12.28% | Revisions=+54% | GrowthEPS=+13.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.37 | Chg30d=+11.90% | Revisions=+0% | GrowthEPS=+8.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +54%